

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhongzhi Pharmaceutical Holdings Limited

中智藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3737)

POSITIVE PROFIT ALERT

This announcement is made by Zhongzhi Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board of directors (“**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary review of the unaudited consolidated management accounts of the Group for the year ended 31 December 2017 and the information currently available to the Board, the Group is expected to record a significant increase of approximately over 25% in net profit for the year ended 31 December 2017 as compared with that of the corresponding period in 2016. Such expected increase is mainly due to the significant increase in the sales of our modern Chinese medicine decoction pieces — Caojinghua cell wall broken herbs.

The information set out in this announcement is only based on the information currently available to the Company and the Board’s preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2017 and is not based on any figure or information which has been audited or reviewed by the Company’s auditors, and may be subject to amendments. Shareholders and potential investors are advised to read the annual results announcement of the Company for the year ended 31 December 2017 which is expected to be published by the end of March 2018.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By Order of the Board
Zhongzhi Pharmaceutical Holdings Limited
Mr. Lai Zhi Tian
Chairman and Executive Director

Hong Kong, 31 January 2018

As at the date of this announcement, the Board comprises eight directors. The executive directors are Mr. Lai Zhi Tian, Ms. Mou Li, Mr. Cao Xiao Jun and Mr. Cheng Jin Le. The non-executive director is Ms. Jiang Li Xia. The independent non-executive directors are Mr. Ng Kwun Wan, Mr. Wong Kam Wah and Mr. Zhou Dai Han.